Company intelligence / Profile preview
Kazia Therapeutics
Sydney, NSW, Australia
- Ownership
- Public · KZIA
- Employees
- ~9
- Development stage
- Phase 2
01
Overview
Kazia’s lead program paxalisib has completed a Phase 2/3 study in glioblastoma as part of the GBM AGILE trial with ongoing discussions for a pivotal registrational study. Paxalisib has also shown encouraging interim data in other brain cancers and received multiple FDA designations including Orphan Drug and Fast Track. EVT801 completed a Phase I study with preliminary positive data presented in late 2024. The company recently sold all rights to Cantrixil to Vivesto AB.
- Therapeutic areas
- Oncology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
15 assets14 more assets in the full pipeline.
Request access →03
Partnerships
Genentech Inc.Evotec SEVivesto AB (licensee of Cantrixil IP)Simcere Pharmaceutical Group Ltd.Global Coalition for Adaptive ResearchQIMR Berghofer Medical Research Institute
04
Financials
- Market cap
- $17.8M
- Total revenue
- $0
- Enterprise value
- $-51.5M
Beyond the preview
Go deeper on Kazia Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kazia Therapeutics.